On September 9, 2021, Obsidian Therapeutics, Inc. closed the transaction. The company issued 76,158,940 shares and received $114,999,999.4 in a round of funding led by new investor TTCG Crossover Management, LLC. The transaction included participation form Vertex Pharmaceuticals Incorporated, new investors RA Capital Management, L.P, Citadel Multi-Strategy Equities Master Fund Ltd. a fund managed by Citadel Advisors LLC, Cowen Healthcare Investments, Deep Track Capital, LP, Logos Capital LLC, Pivotal BioVenture Partners LLC, Samsara BioCapital LLC, Soleus Capital, returning investors Atlas Venture L.P, Vertex Ventures HC, Amgen Ventures, and Bristol-Myers Squibb Company.

As part of the transaction Cariad Chester from TCG Crossover Management, LLC had joined the company's board.